Premium
O3‐01‐07: Rate of decline in ADNI normal controls with evidence of amyloid burden
Author(s) -
Donohue Michael,
Gamst Anthony,
Thomas Ron,
Brewer Jim,
Weiner Michael,
Aisen Paul
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.395
Subject(s) - medicine , entorhinal cortex , cohort , alzheimer's disease neuroimaging initiative , hippocampus , amyloid (mycology) , pittsburgh compound b , cognitive decline , oncology , alzheimer's disease , cardiology , gastroenterology , endocrinology , disease , pathology , dementia
Additionally, beta-amyloid area levels were highly associated with clinical dementia (P < 0.005), whereas CERAD plaque scores were not (P 1⁄4 0.22) Conclusions: In the oldest-old, APOE2 was associated with increased CERAD plaque staging, but not increased beta-amyloid percent area. This lower level of percent area may reflect lower total beta-amyloid and may be responsible for the APOE2 carriers’ decreased risk of dementia, despite high CERAD plaque staging. Conversely, APOE4 carriers have both increased CERAD plaque staging and total beta-amyloid, which may be associated with their increased risk of clinical dementia. Therefore, findings from APOE2 carriers highlight the poor relationship between CERAD staging and cognition, and suggest that other measures of total beta-amyloid are more related to cognition in this age group. Consequently, the neuropathological criteria for AD may need to be reevaluated in this age group.